About this item:
454 Views | 59 Downloads
Author Notes:
Correspondence: Javed Butler, MD MPH, Emory Clinical Cardiovascular Research Institute, 1462 Clifton Road NE, Suite 504, Atlanta, GA 30322; Tel #: (404) 778 5273; Fax #: (404) 778-5285; Email: javed.butler@emory.edu
Disclosures: No conflict of interest
Subject:
Research Funding:
Supported in part by (a) PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources and (b) Grant 1U10HL110302-01 from the National Institutes of Health, National Heart, Lung, and Blood Institute.
Clinical Adoption of Prognostic Biomarkers The Case for Heart Failure
Tools:
Abstract:
The recent explosion of scientific knowledge and technological progress has led to the discovery of a large array of circulating molecules commonly referred to as biomarkers. Biomarkers in heart failure research have been used to provide pathophysiological insights, aid in establishing the diagnosis, refine prognosis, guide management, and target treatment. However, beyond diagnostic applications of natriuretic peptides, there are currently few widely recognized applications for biomarkers in heart failure. This represents a remarkable discordance considering the number of molecules that have been shown to correlate with outcomes, refine risk prediction, or track disease severity in heart failure in the past decade. In this article, we use a broad framework proposed for cardiovascular risk markers to summarize the current state of biomarker development for heart failure patients. We utilize this framework to identify the challenges of biomarker adoption for risk prediction, disease management, and treatment selection for heart failure and suggest considerations for future research.
Copyright information:
© 2012 Elsevier Inc. All rights reserved.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/).
